ORIGINAL RESEARCH article
Front. Neurol.
Sec. Neuro-Oncology and Neurosurgical Oncology
Volume 16 - 2025 | doi: 10.3389/fneur.2025.1656490
Integrative Multi-Omics Analysis Identifies TGFA as a Novel Glioma Susceptibility Gene and Therapeutic Target
Provisionally accepted
- 1Capital Medical University, Beijing, China
- 2Beijing Tiantan Hospital, Capital Medical University, Beijing, China
- 3Zhejiang University, Hangzhou, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: Gliomas are among the most aggressive brain tumors, with high mortality and limited treatments. Despite genetic advances, their molecular mechanisms remain unclear, hindering diagnostic biomarkers and targeted therapies. This study investigates novel glioma susceptibility genes using integrative multi-omics. Methods: Cross-tissue transcriptome-wide association analyses integrated glioma GWAS data with eQTLs from 49 GTEx v8 tissues, utilizing UTMOST (cross-tissue), FUSION (single-tissue), and MAGMA (gene-level). Prioritized genes underwent Mendelian randomization, Bayesian colocalization, and phenome-wide association. TGFA expression was assessed in glioma samples via public genomic repositories and immunohistochemistry. Drug repurposing employed Comparative Toxicogenomics Database (CTD) and CB-Dock2 for molecular docking. Results: Five candidate genes were identified (SLC16A8, TGFA, PLA2G6, MAFF, TMEM184B), with Transforming Growth Factor Alpha (TGFA) as the strongest candidate. TGFA showed significant glioma associations across brain tissues and causal relationships via Mendelian randomization (OR: 1.27–1.39), supported by Bayesian colocalization. Elevated TGFA expression occurred in WHO grade 2/3 gliomas and 1p/19q co-deleted tumors, validated by immunohistochemistry. Drug repurposing identified 40 FDA-approved TGFA-targeting drugs; irinotecan exhibited the highest binding affinity (–62.0 kcal/mol) in docking studies. Discussion: TGFA is a novel glioma susceptibility gene with subtype-specific expression. Its therapeutic targeting offers opportunities for precision therapy, potentially advancing glioma clinical management.
Keywords: Glioma, TGFA, Multi-omics analysis, transcriptome-wide association study, drug repurposing
Received: 18 Jul 2025; Accepted: 10 Oct 2025.
Copyright: © 2025 Jiang, Tu, Ji, Liu, Yu and Zhao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Kefu Yu, kefu006@163.com
Zhigang Zhao, 13910612086@163.com
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.